Novo Nordisk’s $380 Million Czech Bet and Record Pill Launch Draw a Line Under a Brutal Selloff

Despite a 42% slide from highs, Novo Nordisk's oral Wegovy pill sees rapid uptake and Medicare coverage from July 2026, with new production investments and strategic R&D shifts.

The Danish pharma giant Novo Nordisk has endured a punishing 42% slide from its 52-week high of 65.20 euros, but a flurry of strategic moves — from a major production investment in the Czech Republic to the breakneck uptake of its oral Wegovy pill — is starting to shift the narrative. The stock, which recently closed up 4.24% at 39.20 euros on a Friday, still trades 8.58% below its 200-day moving average of 41.23 euros, and the year-to-date loss stands at 15.64%, having widened from an earlier 12% retreat as initial setbacks compounded.

The worst of the pain was triggered by disappointing head-to-head data for CagriSema, Novo Nordisk’s experimental obesity therapy. Patients lost about 23% of their weight after 84 weeks, compared with 25.5% for Eli Lilly’s Zepbound — a gap that the market had not anticipated. The stock tumbled 16% in a single session, and nearly 51% of CagriSema recipients achieved a body mass index below 30. Novo Nordisk submitted the drug to the U.S. Food and Drug Administration in December 2025, with a decision expected by end of 2026. Meanwhile, first-quarter revenue reached 70.1 billion Danish kroner, down 4% year over year, though the strength of the new oral formulation helped soften the blow.

That oral formulation — the Wegovy pill — became the first approved oral GLP-1 for weight loss when the FDA cleared it in December 2025. By April 2026, Novo Nordisk was filling more than 200,000 weekly prescriptions, and over one million Americans began therapy within the first four months. The company described it as the fastest launch in its history, and on the day of the Q1 earnings release, the shares gained 3%.

An even larger catalyst looms in July 2026, when the Medicare Bridge Program begins covering Wegovy for eligible U.S. seniors. For the first time, Medicare will reimburse a pure weight-loss medication, with a monthly copay of just $50. An estimated 3.4 million beneficiaries will qualify in the first six months, opening a vast new patient pool. The European Medicines Agency has already recommended approval of the oral pill, and a launch outside the U.S. is slated for the second half of 2026.

Behind the scenes, Novo Nordisk is overhauling its research operations to concentrate on metabolic disease. It closed its internal cell therapy unit in October 2025 and in May 2026 handed off its Parkinson’s candidates to the AI startup Cellular Intelligence, significantly reducing early-stage risk. The Novo Nordisk Foundation is also funding the CardioMetabolic Bridge initiative with around 60 million euros over six years to accelerate the translation of academic discoveries into commercial drugs. The first specialized lab opens this month in London, with additional sites planned in Germany and Italy.

To meet surging demand for its existing portfolio, the company is investing roughly $380 million in new production lines in the Czech Republic, where it already manufactures proteins for next-generation medicines, and another $30 million in assembly lines in China. These moves come alongside a 15 billion Danish kroner share buyback program that is providing ongoing support to the stock.

Technically, the stock is balancing between fear and hope. The relative strength index sits at 51.2, signaling neutral territory. The 52-week low of 30.25 euros is 24.6% below the current price, and the stock has recently managed to hold above its 50-day moving average — a pattern that could refocus attention on the long-term downtrend. The bears have had their say: Eli Lilly’s superior efficacy head start, the CagriSema stain, and a forecast for full-year revenue to fall by 4% to 12% are all well documented. But with a record-breaking pill launch, a Medicare windfall, an EU approval on the horizon, and a potential CagriSema green light before year-end, the pendulum may be swinging back toward upside surprise.